CCL

Összesen 7 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM117407
035-os BibID:(WoS)001143857500001 (Scopus)85180605811
Első szerző:Ghansah, Harriet (PhD)
Cím:Low factor XIII levels and altered fibrinolysis in patients with multiple myeloma / Harriet Ghansah, Rita Orbán-Kálmándi, Ildikó Beke Debreceni, Éva Katona, László Rejtő, László Váróczy, Linda Lóczi, Bas de Laat, Dana Huskens, János Kappelmayer, Zsuzsa Bagoly
Dátum:2024
ISSN:0049-3848
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Thrombosis Research. - 234 (2024), p. 12-20. -
További szerzők:Orbán-Kálmándi Rita Angéla (1993-) (klinikai laboratóriumi kutató) Bekéné Debreceni Ildikó (1970-) (biológus) Katona Éva (1961-) (klinikai biokémikus) Rejtő László (1963-) (belgyógyász, haematológus) Váróczy László (1974-) (belgyógyász, haematológus) Lóczi Linda Laat, Bas de Huskens, Dana Kappelmayer János (1960-) (laboratóriumi szakorvos) Bagoly Zsuzsa (1978-) (orvos)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM106630
035-os BibID:(Scopus)85146863664 (WoS)000927329500001
Első szerző:Ghansah, Harriet (PhD)
Cím:Patients with multiple myeloma and monoclonal gammopathy of undetermined significance have variably increased thrombin generation and different sensitivity to the anticoagulant effect of activated protein C / Harriet Ghansah, Ildikó Beke Debreceni, László Váróczy, László Rejtő, Linda Lóczi, Zsuzsa Bagoly, János Kappelmayer
Dátum:2023
ISSN:0049-3848
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Thrombosis Research. - 223 (2023), p. 44-52. -
További szerzők:Bekéné Debreceni Ildikó (1970-) (biológus) Váróczy László (1974-) (belgyógyász, haematológus) Rejtő László (1963-) (belgyógyász, haematológus) Lóczi Linda Bagoly Zsuzsa (1978-) (orvos) Kappelmayer János (1960-) (laboratóriumi szakorvos)
Pályázati támogatás:GINOP-2.3.2-15-2016-00043
GINOP
FK128582
OTKA
1Q4DBKX4 STIP320
Egyéb
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

3.

001-es BibID:BIBFORM106027
035-os BibID:(cikkazonosító)912664 (scopus)85137215772 (wos)000882813200001
Első szerző:Lóczi Linda
Cím:Thrombin generation as a predictor of outcomes in patients with non-traumatic intracerebral hemorrhage / Lóczi Linda, Orbán-Kálmándi Rita, Árokszállási Tamás, Fekete István, Fekete Klára, Héja Máté, Tóth Judit, Csiba László, Bagoly Zsuzsa
Dátum:2022
ISSN:1664-2295
Megjegyzések:Background: Non-traumatic intracerebral hemorrhage (ICH) accounts for 10-15% of all strokes and leads to a higher rate of mortality as compared to ischemic strokes. We aimed to find out whether the thrombin generation assay (TGA) could predict outcomes in patients with ICH. Patients and methods: In this prospective, observational study, 87 consecutive patients with ICH and 164 healthy controls were included. Computed tomography (CT), detailed clinical investigation, and laboratory investigations were performed from patients on admission. TGA was performed using stored platelet poor plasma obtained on admission. Lag time, endogen thrombin potential (ETP), peak thrombin, and time to peak parameters were calculated. Short- and long-term outcomes of ICH were defined at 14 days and 3 months post-event according to the NIHSS and the modified Rankin Scale (mRS), respectively. Results: Peak thrombin was significantly higher in patients as compared to controls (397.2 ? 93.9 vs. 306 ? 85.3 nM, p < 0.0001). Lag time, ETP, and time to peak parameters showed a significant positive correlation with CRP in both groups. In patients with worse long-term functional outcomes, peak thrombin was significantly higher as compared to those with favorable outcomes [mRS 2-6 median: 402.5 (IQR:344.8-473.8) vs. mRS 0-1: 326.4 (294.2-416.1) nM, p = 0.0096]. Based on the statistically optimal threshold of 339.1 nM peak thrombin, the sensitivity and specificity of this parameter to determine mRS 2-6 as an outcome were 80.8 and 64.7%, respectively. In a binary logistic regression model including age, sex, BMI, smoking status, NIHSS on admission, D-dimer, and peak thrombin (>339.1 nM), only NIHSS and the peak thrombin parameters remained in the model as significant, independent predictors of poor outcome. Lag time and time to peak showed a modest, significant negative correlation with intracerebral bleeding volume on admission (r = -0.2603, p = 0.0231 and r = -0.3698, p = 0.0010, respectively). During the follow-up of patients, estimated hemorrhage volumes on day 90 showed significant positive association with the ETP and peak thrombin parameters (r = 0.3838, p = 0.0363 and r = 0.5383, p = 0.0021, respectively). Conclusion: In patients with ICH, TG was increased as compared to healthy controls, which might be explained by the presence of higher inflammatory parameters in patients. Peak thrombin measured on admission might be a useful tool to predict outcomes in patients with ICH.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Frontiers in Neurology. - 13 (2022), p. 1-12. -
További szerzők:Orbán-Kálmándi Rita Angéla (1993-) (klinikai laboratóriumi kutató) Árokszállási Tamás (1988-) (neurológus) Fekete István (1951-) (neurológus, pszichiáter) Fekete Klára (1978-) (neurológus) Héja Máté (1991-) (általános orvos) Tóth Judit (1964-) (radiológus) Csiba László (1952-) (neurológus, pszichiáter) Bagoly Zsuzsa (1978-) (orvos)
Pályázati támogatás:GINOP-2.3.2-15-2016-00043
GINOP
K120042
OTKA
FK128582
OTKA
ELKH-DE 332 Cerebrovascular and Neurodegenerative Research Group
Egyéb
ÚNKP 20-3-I-DE-220
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM082985
035-os BibID:(PMID)31808421
Első szerző:Lóczi Linda
Cím:Antiphospholipid syndrome and the risk of myocardial infarction : current evidence and uncertainties / Linda Lóczi, János Kappelmayer, Tünde Tarr, Zsuzsa Bagoly
Dátum:2020
ISSN:0022-9032
Megjegyzések:Antiphospholipid syndrome (APS) encompasses a wide spectrum of disease manifestations that may prevail in the form of venous or arterial thrombosis or lead to pregnancy complications in the presence of persisting antiphospholipid antibodies (aPL). Unlike in the case of congenital thrombophilias, in which venous thromboses are more likely to occur as compared with arterial events, aPL may cause thrombosis in both types of vascular systems. Arterial thrombosis in APS is fairly common and often involve coronary or cerebral arteries leading to myocardial infarction (MI) or stroke. In this review, we summarize the complex pathomechanisms leading to aPL?associated thrombosis and list challenges during the laboratory detection of these antibodies. Specific features of MI in patients with APS are summarized based on a comprehensive literature search of available case reports. Preventive and treatment strategies are discussed based on the current recommendations and most recent evidence. We conclude that the risk of MI in patients with APS is considerable and MI may be the first manifestation of the disease. MI in APS shows specific clinical features including relatively young age at presentation, no sex dominance, often normal coronaries without the sign of atherosclerosis, high risk of recurrent thrombotic events. Treatment of acute MI in patients with APS is often challenging and adverse events, including stent thrombosis, are more frequent as compared with patients without APS. Preventive strategies in APS should be personalized and include strict management of additional cardiovascular risk factors and long?term anticoagulation with vitamin K antagonists. Current evidence does not support the use of direct oral anticoagulants in the management of patients with APS with arterial thrombosis due to the high risk of recurrent events.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Kardiologia Polska. - 78 : 1 (2020), p. 6-14. -
További szerzők:Kappelmayer János (1960-) (laboratóriumi szakorvos) Tarr Tünde (1976-) (belgyógyász, allergológus és klinikai immunológus) Bagoly Zsuzsa (1978-) (orvos)
Pályázati támogatás:FK128582
OTKA
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM116355
035-os BibID:(cikkazonosító)1257072 (WoS)001100984900001 (Scopus)85176425171
Első szerző:Stercel Vivien
Cím:Effect of anti-SARS-CoV-2 BNT162b2 mRNA vaccination on thrombin generation in children with inflammatory bowel disease / Stercel Vivien, Lóczi Linda, Kadenczki Orsolya, Nemes Éva, Nagy Béla, Hodossy-Takács Rebeka, Szabó Attila Ádám, Fagyas Miklós, Kappelmayer János, Szabó Tamás, Bagoly Zsuzsa
Dátum:2023
ISSN:1664-3224
Megjegyzések:Background: Inflammatory bowel disease (IBD) including Crohn's disease (CD) and ulcerative colitis (UC), are associated with higher thrombotic risk and enhanced thrombin generation (TG) in adults. Despite encouraging data reporting vaccine safety and low IBD flare rates in adults with IBD, vaccine hesitancy was demonstrated to be high in families of children with IBD. We aimed to find out whether TG is increased in children with IBD as compared to healthy controls and whether TG parameters show significant changes following SARS-CoV-2 mRNA vaccination.Patients and methodsIn this observational case-control study, 38 children with IBD (CD:18, UC: 20) aged 12-18 years and 62 healthy age-and sex-matched children were enrolled. Blood was collected before the first dose and 2-6 weeks after the second dose of BNT162b2 (Pfizer-BioNTech) mRNA vaccine dose. Blood cell counts, fibrinogen, inflammatory markers (hsCRP, ferritin), anti-SARS-CoV-2 antibody levels were investigated, TG assay was carried-out using platelet-poor plasma. Detailed clinical parameters including disease activity scores (PUCAI, PCDAI) were registered pre-and post- vaccination. A guided questionnaire was used to collect data on adverse reactions (AEs) post- vaccination. Results: Baseline TG parameters did not differ between patients and controls. Endogenous thrombin potential showed a significant positive correlation with markers of inflammation and with PCDAI. Inflammatory parameters and TG did not increase in patients and controls post-vaccination. Vaccination significantly increased antibody levels in all three investigated groups, but post-vaccination anti-SARS-CoV-2 S IgG/IgM levels were below the 5th percentile value of healthy children in more than one third of patients. Those receiving TNF alpha inhibitor therapy presented significantly lower SARS-CoV-2 S IgG/IgM levels as compared to patients on other immunosuppressive regimens. Systemic AEs did not differ between patients and controls while lower rate of local symptoms was found post-vaccination in children with IBD. Only 2 IBD flares were detected 2-6 weeks after the second dose of vaccination. Conclusion: Our study is the first to support the safety and efficacy of anti-SARS-CoV-2 BNT162b2 vaccination in children with IBD with detailed pre-and post-vaccination laboratory data including TG. Results of this study may further increase confidence and reduce vaccine hesitancy in caretakers of pediatric IBD patients.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
COVID-19
Crohn's disease
inflammatory bowel disease
severe acute respiratory syndrome coronavirus-2
thrombin generation
ulcerative colitis
Megjelenés:Frontiers in Immunology. - 14 (2023), p. 1-12. -
További szerzők:Lóczi Linda Kadenczki Orsolya (1974-) (csecsemő- és gyermekgyógyász) Nemes Éva (1957-) (csecsemő- és gyermekgyógyász, gasztroenterológus) Nagy Béla Jr. (1980-) (labordiagnosztikai szakorvos) Hodossy-Takács Rebeka (1997-) (orvos) Szabó Attila Ádám (1996-) (orvos) Fagyas Miklós (1984-) (orvos) Kappelmayer János (1960-) (laboratóriumi szakorvos) Szabó Tamás (1968-) (gyermekgyógyász) Bagoly Zsuzsa (1978-) (orvos)
Pályázati támogatás:FK128582
NKFIH
K147243
NKFIH
K129287
NKFIH
TKP 2021 EGA-19
Egyéb
UNKP 22-3-II-DE-167
Egyéb
UNKP 23-5-DE-482
Egyéb
POST-COVID2021-33
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM103252
035-os BibID:(cikkazonosító)901286 (WoS)000886464200001 (Scopus)85135188784
Első szerző:Székely Edina Gabriella
Cím:Low [alfa]2-Plasmin Inhibitor Antigen Levels on Admission Are Associated With More Severe Stroke and Unfavorable Outcomes in Acute Ischemic Stroke Patients Treated With Intravenous Thrombolysis / Székely Edina Gabriella, Orbán-Kálmándi Rita, Szegedi István, Katona Éva, Baráth Barbara, Czuriga-Kovács Katalin Réka, Lóczi Linda, Vasas Nikolett, Fekete István, Fekete Klára, Berényi Ervin, Oláh László, Csiba László, Bagoly Zsuzsa
Dátum:2022
ISSN:2297-055X
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Frontiers in Cardiovascular Medicine. - 9 (2022), p. 1-14. -
További szerzők:Orbán-Kálmándi Rita Angéla (1993-) (klinikai laboratóriumi kutató) Szegedi István (1969-) (hematológus, onkológus, nefrológus) Katona Éva (1961-) (klinikai biokémikus) Baráth Barbara (1991-) (orvosírnok) Czuriga-Kovács Katalin Réka (1981-) (neurológus) Lóczi Linda Molnárné Vasas Nikolett (1987-) (élettanász) Fekete István (1951-) (neurológus, pszichiáter) Fekete Klára (1978-) (neurológus) Berényi Ervin (1964-) (radiológus) Oláh László (1967-) (neurológus) Csiba László (1952-) (neurológus, pszichiáter) Bagoly Zsuzsa (1978-) (orvos)
Pályázati támogatás:GINOP-2.3.2-15-2016-00043
GINOP
K120042
OTKA
FK128582
OTKA
K120633
OTKA
UNKP-21-4-1
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM118894
035-os BibID:(cikkazonosító)1329236 (WoS)001152827800001 (Scopus)85186581723
Első szerző:Tóth Eszter Lilla
Cím:Case report : Complex evaluation of coagulation, fibrinolysis and inflammatory cytokines in a SARS-CoV-2 infected pregnant woman with fetal loss / Tóth Eszter Lilla, Orbán-Kálmándi Rita, Bagoly Zsuzsa, Lóczi Linda, Deli Tamás, Török Olga, Molnár Sarolta, Baráth Sándor, Singh Parvind, Hevessy Zsuzsanna, Katona Éva, Fagyas Miklós, Szabó Attila Ádám, Molnár Szabolcs, Krasznai Zoárd Tibor
Dátum:2024
ISSN:1664-3224
Megjegyzések:Background: SARS-CoV-2 infection during pregnancy increases the risk of severe obstetrical complications. Detailed evaluation of COVID-19-associated coagulopathy in a pregnancy with stillbirth hasn't been described so far. Besides knowledge gaps in the pathomechanism leading to stillbirth in COVID-19 pregnancies, currently, no prognostic biomarker is available to identify pregnant patients who are at imminent risk of COVID-19-associated maternal and fetal complications, requiring immediate medical attention. Case: Here we report the case of a 28-year-old SARS-CoV-2 infected pregnant patient, admitted to our hospital at 28 weeks of gestation with intrauterine fetal loss. The presence of SARS-CoV-2 placentitis was confirmed by immunohistological evaluation of the placenta. She had only mild upper respiratory symptoms and her vital signs were within reference throughout labor and postpartum. The stillborn infant was delivered per vias naturales. Fibrinogen concentrate was administered before and after labor due to markedly decreased fibrinogen levels (1.49 g/l) at admission and excessive bleeding during and after delivery. Although coagulation screening tests were not alarming at admission, the balance of hemostasis was strikingly distorted in the patient. As compared to healthy age- and gestational age-matched pregnant controls, increased D-dimer, low FVIII activity, low FXIII level, marked hypocoagulability as demonstrated by the thrombin generation assay, together with shortened clot lysis and decreased levels of fibrinolytic proteins were observed. These alterations most likely have contributed to the increased bleeding observed during labor and in the early postpartum period. Interestingly, at the same time, only moderately altered inflammatory cytokine levels were found at admission. Serum ACE2 activity did not differ in the patient from that of age- and gestational age-matched healthy controls, suggesting that despite previous speculations in the literature, ACE2 may not be used as a potential biomarker for the prediction of COVID-19 placentitis and threatening fetal loss in SARS-CoV-2-infected pregnancies. Conclusions: Although based on this case report no prognostic biomarker could be identified for use in pregnant patients with imminent risk of fetal loss associated with COVID-19 placentitis, the above-described hemostasis alterations warrant awareness of postpartum hemorrhagic complications and could be helpful to identify patients requiring intensified medical attention.
Tárgyszavak:Orvostudományok Klinikai orvostudományok esettanulmány
folyóiratcikk
COVID 19
fetal death
hemostasis
placenta
case report
stillbirth
Megjelenés:Frontiers in Immunology. - 15 (2024), p. 1-10. -
További szerzők:Orbán-Kálmándi Rita Angéla (1993-) (klinikai laboratóriumi kutató) Bagoly Zsuzsa (1978-) (orvos) Lóczi Linda Deli Tamás (1979-) (szülész-nőgyógyász, endokrinológus szakorvos) Török Olga (1956-) (szülész-nőgyógyász, humángenetikus) Deliné Molnár Sarolta (1990-) (patológus) Baráth Sándor (1977-) (biológus) Singh, Parvind (1995-) (PhD hallgató) Hevessy Zsuzsanna (1966-) (laboratóriumi szakorvos) Katona Éva (1961-) (klinikai biokémikus) Fagyas Miklós (1984-) (orvos) Szabó Attila Ádám (1996-) (orvos) Molnár Szabolcs (1987-) (szülész-nőgyógyász szakorvos) Krasznai Zoárd Tibor (1973-) (szülész-nőgyógyász, gyermeknőgyógyász)
Pályázati támogatás:NKFI FK128582
Egyéb
TKP 2021 EGA-19
Egyéb
ÚNKP 22-3-II-DE-167
Egyéb
ÚNKP-23-5-DE-482
Egyéb
POST-COVID2021-33
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.